Alector Inc
$ 1.45
0.00%
26 Dec - close price
- Market Cap 158,270,000 USD
- Current Price $ 1.45
- High / Low $ 1.48 / 1.40
- Stock P/E N/A
- Book Value 0.54
- EPS -1.06
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -1.22 %
- 52 Week High 3.40
- 52 Week Low 0.87
About
Alector, Inc. (ALEC) is a pioneering clinical-stage biopharmaceutical company engaged in the development of transformative therapies for neurodegenerative diseases, including Alzheimer's disease and frontotemporal dementia. Utilizing its proprietary immuno-neurology platform, Alector aims to leverage the immune system to restore neuronal health and function, positioning itself at the forefront of neurological innovation. Based in South San Francisco, the company boasts a promising pipeline of differentiated product candidates, poised to potentially reshape treatment paradigms and significantly improve patient outcomes in a field marked by high unmet medical need.
Analyst Target Price
$2.06
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-05 | 2024-08-07 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-03 | 2023-05-04 | 2023-02-28 |
| Reported EPS | -0.34 | -0.3 | -0.41 | -0.02 | -0.43 | -0.4 | -0.38 | -0.49 | -0.53 | 0.02 | -0.55 | -0.63 |
| Estimated EPS | -0.4 | -0.47 | -0.51 | -0.5443 | -0.53 | -0.5 | -0.51 | -0.77 | -0.66 | -0.82 | -0.76 | -0.46 |
| Surprise | 0.06 | 0.17 | 0.1 | 0.5243 | 0.1 | 0.1 | 0.13 | 0.28 | 0.13 | 0.84 | 0.21 | -0.17 |
| Surprise Percentage | 15% | 36.1702% | 19.6078% | 96.3256% | 18.8679% | 20% | 25.4902% | 36.3636% | 19.697% | 102.439% | 27.6316% | -36.9565% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3913 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALEC
2025-12-26 18:09:07
Levi & Korsinsky LLP has launched an investigation into Alector, Inc. (ALEC) following a significant stock price drop. This investigation concerns possible violations of federal securities laws after Alector announced that its Phase 2 clinical trial for latozinemab in FTD-GRN patients did not demonstrate a clinical benefit. The news led to ALEC's stock price falling over 52%.
2025-12-23 19:08:54
Levi & Korsinsky has launched an investigation into Alector, Inc. (ALEC) concerning potential federal securities law violations. This investigation follows a significant 52% drop in ALEC's stock price after the company announced on October 22, 2025, that its Phase 2 INFRONT-3 clinical trial for latozinemab (AL001) failed to demonstrate a clinical benefit in slowing the progression of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The firm encourages aggrieved shareholders to seek additional information regarding the lawsuit.
2025-12-23 07:32:00
Levi & Korsinsky has launched an investigation into Alector, Inc. (ALEC) for potential federal securities law violations. This comes after Alector's announcement on October 22, 2025, that its latozinemab treatment (AL001) in the Phase 2 INFRONT-3 clinical trial did not show clinical benefit for slowing FTD-GRN progression, causing ALEC's stock to drop over 52%. The firm is inviting affected investors to seek additional information regarding the possible securities fraud.
2025-12-22 19:09:45
Levi & Korsinsky has initiated an investigation into Alector, Inc. (NASDAQ: ALEC) for potential federal securities law violations. This comes after Alector announced on October 22, 2025, that its latozinemab drug did not show clinical benefit in slowing frontotemporal dementia progression, causing the stock price to drop over 52%. Investors are encouraged to contact Levi & Korsinsky for more information regarding potential securities fraud allegations.
2025-12-19 19:09:26
Levi & Korsinsky has initiated an investigation into Alector, Inc. (NASDAQ: ALEC) following a significant drop in its stock price. This investigation comes after Alector announced that its Phase 2 clinical trial for latozinemab (AL001) in frontotemporal dementia did not show clinical benefit, causing the stock to fall over 52%. Shareholders who lost money are encouraged to contact Levi & Korsinsky for more information regarding potential federal securities law violations.
2025-12-19 19:09:09
Levi & Korsinsky has initiated an investigation into Alector, Inc. (ALEC) regarding potential violations of federal securities laws. This follows Alector's announcement of negative results from its Phase 2 clinical trial for latozinemab, which caused ALEC's stock price to drop significantly by over 52%. The firm is inviting affected shareholders to contact them for more information on the securities fraud investigation.
